アダルト ADHD 治療

Introduction

With the recent medical classification of adult ADHD and potentially twice the number of patients compared to pediatric ADHD, manufacturers are seeking new indications in this expanding and lucrative market. Lilly's Strattera was the first drug to exploit this, and is forecast to reach blockbuster status by 2006. Consequently, manufacturers will need to differentiate their products from Strattera.

Scope

• Overview of the epidemiology of adult ADHD, with an assessment of the untapped patient potential
• Discussion of the problems facing physicians in the diagnosis of adult ADHD
• Analysis of the current market leaders and primary contenders for market entry, with adult ADHD-specific market forecasts
• Exploration of product positioning and life-cycle management strategies currently used by Strattera, Adderall XR and Concerta

Report Highlights

Strattera was the first drug approved for the treatment of adult ADHD in November 2002. Since launch Strattera has a steady sales increase from $55m in Q1 2003 to $133m in Q4 2003, and Datamonitor has forecast Strattera to reach blockbuster status by 2006.

Shire's Adderall XR recently received an approvable letter from the FDA for adult ADHD and J&J's Concerta is currently in Phase III with an expected launch in 2005. Datamonitor forecasts that both drugs will see an increase in sales from gaining an indication for this market, although both will also experience a decline in revenues post 2005.

Approximately 75% of adults with ADHD present with a comorbid condition, of which anxiety and depressive disorders predominate. Datamonitor has highlighted two drug classes, which may benefit from further investigation of the treatment of such comorbidities in order to increase their market share in the adult ADHD market.

Reasons to Purchase

• Analyze the commercial viability of the adult ADHD market, based on estimated patient numbers
• Develop market entry and consolidation strategies through an understanding of key unmet needs in the market
• Identify and assess novel R&D compounds in the adult ADHD pipeline

Table of Contents

EXECUTIVE SUMMARY

Introduction

Scope and coverage of the Brief

Key findings about the the topic

Strattera was the first drug approved for the treatment of adult ADHD in November 2002. Since launch, Strattera sales have steadily increased from $55m in Q1 2003 to $133m in Q4 2003, and Datamonitor expects Strattera to reach blockbuster status by 2006.

Shire's Adderall XR recently received an approvable letter from the FDA for an indication in adult ADHD and J&J's Concerta is currently in Phase III with an expected launch in 2005. Datamonitor forecasts that both drugs will see an increase in sales from gaining an indication for this market although both will also experience a decline in revenues post 2005.

It is currently estimated that approximately 75% of adults with ADHD present with a comorbid condition, of which anxiety and depressive disorders predominate. Datamonitor has highlighted two drug classes that may benefit from further investigation of the treatment of such comorbidities in order to increase their market share in the adult ADHD market.

DISEASE OVERVIEW

Disease definition

Etiology of ADHD

Structural abnormalities

Genetic predisposition

Neurotransmitter dysfunction

Dopaminergic genes

DSM-IV diagnostic criteria of ADHD

Progression of symptoms from pediatric to adult ADHD

Epidemiology

Prevalence of adult ADHD

Segmentation of adult ADHD

Gender

Comorbidities

Anxiety and mood comorbidities

Substance abuse

DIAGNOSIS

Diagnostic guidelines

History of symptoms

Diagnostic rate

TREATMENT

Treatment guidelines

Pharmacological treatment

Stimulants

Stimulants for adult ADHD

Adderall XR

The clinical data supporting Adderall for the treatment of adult ADHD

Adderall XR forecast

Opportunities for Shire and Adderall XR

Concerta

Concerta forecast

Opportunities for J&J and Concerta

Non-stimulants

Strattera

The clinical data supporting Strattera for the treatment of adult ADHD

Strattera forecast

Opportunuities for Lilly and Strattera

Antidepressants

Off-label prescribing

PIPELINE ANALYSIS

Unmet needs

Pipeline drugs

Methypatch

SPD-503

Backlash to adult ADHD?

APPENDIX

Bibliography

Websites

Research methodology

Disclaimer

List of Tables

Table 1: Symptoms of ADHD in children and adults.

Table 2: Comorbid disorders with ADHD

Table 3: ADHD diagnostic tools

Table 4: Stimulants for ADHD

Table 5: Adderall sales forecast to 2008

Table 6: Concerta sales forecast to 2008

Table 7: Non-stimulants for ADHD

Table 8: Strattera sales forecast to 2008

Table 9: Forecast sales for ADHD drugs approved for both child and adult markets, 2002-08

Table 10: Late stage pipeline ADHD drugs, 2004

List of Figures

Figure 1: Prevalence of adults with ADHD in the general population across the seven major markets, 2004

Figure 2: Assessment of adults presenting with symptoms of ADHD

Figure 3: Diagnosis rate of ADHD across the seven major markets, 2004

Figure 4: ADHD pharmacological treatment algorithm

Figure 5: ADHD patients receiving pharmacological treatment, 2004

Figure 6: Adderall study for adult ADHD

Figure 7: Adderall XR study in adult ADHD

Figure 8: Adderall sales forecast to 2008

Figure 9: Release rate of Concerta and resulting serum levels

Figure 10: Concerta sales forecast to 2008

Figure 11: Strattera sales forecast to 2008

Figure 12: Sales of ADHD drugs ($m), Q3 2000(Q2 2003

Figure 13: Methypatch sales forecast to 2008

Figure 14: Lilly's Adult Self-Report Scale